Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is determine the safety of 5-fluorouracil, bevacizumab and erlotinib when administered in combination with external beam radiation therapy(Phase I portion) as well as to begin to collect information about whether this combination treatment is effective in treating(Phase II portion) patients with locally advanced rectal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer

NCT00052559

Adenocarcinoma of the Rectum Stage II Rectal Cancer Stage III Rectal Cancer

COMPLETED PHASE1

Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer

NCT00118261

Colorectal Cancer

COMPLETED PHASE1

Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

NCT00116506

Colorectal Cancer Neoplasm Metastasis

COMPLETED PHASE2

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

NCT00321685

Rectal Adenocarcinoma Stage II Rectal Cancer AJCC v7 Stage III Rectal Cancer AJCC v7

COMPLETED PHASE2

Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

NCT00611858

Rectal Cancer

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* All participants will receive the following drugs: 5-fluorouracil (5-FU) given as a continuous 24-hour infusion; Bevacizumab given intravenously; erlotinib given orally at home. In the Phase I portion, we are looking for the highest dose of erlotinib that can be given safely in combination with the 5-FU, bevacizumab and radiation therapy. Therefore the dose of erlotinib may not be the same for each participant. The dose will increase until we find the highest dose without causing serious or unmanageable side effects.
* Study treatment is given as an outpatient and consists of 14 day cycles with a total of 3 cycles. Patients will be given all three study drugs and radiation therapy on a monday (unless a monday falls on on a holiday). This will be day 1 of the first treatment cycle. 5-FU is given continuously days 1-14. Bevacizumab is given on day 1. Erlotinib will be given on days 1-14. Radiation therapy will be performed on Days 1-5 and 8-12.
* The following tests and procedures will be performed weekly while participants are receiving study treatment: physical examination, measurement of vital signs, height and weight; performance status; blood work, urine sample.
* At the end of treatment the following tests will be performed: physical examination and measurement of vital signs; performance status; blood work; CT scans of chest, abdomen and pelvis. Patients will also be evaluated for surgery at this time. Patients will be followed every three months for the first three years after surgery, then every 6 months for the next two years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectal Cancer Adenocarcinoma of the Rectum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chemotherapy and radiation

Continuous infusion 5-fluorouracil 225 mg/M2/d, bevacizumab 5 mg/kg IV q 14 days, erlotinib 50-150 mg orally daily for duration of radiation.

Group Type EXPERIMENTAL

5-fluorouracil

Intervention Type DRUG

Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.

bevacizumab

Intervention Type DRUG

Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.

erlotinib

Intervention Type DRUG

Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.

External beam radiation therapy (EBRT)

Intervention Type PROCEDURE

Given on days 1-5 and 8-12

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

5-fluorouracil

Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.

Intervention Type DRUG

bevacizumab

Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.

Intervention Type DRUG

erlotinib

Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.

Intervention Type DRUG

External beam radiation therapy (EBRT)

Given on days 1-5 and 8-12

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed primary adenocarcinoma of the rectum that begins within 15cm of the anal verge as determined by sigmoidoscopy or colonoscopy
* Clinical T3 or T4 tumors as determined by endoscopic ultrasound and/or rectal MRI
* ECOG performance status of 0-2
* 18 years of age or older
* Creatinine of \< 2.0
* Adequate hepatic function
* Adequate hematopoietic function
* Use of effective means of contraception in subjects of child-bearing potential

Exclusion Criteria

* Evidence of metastatic disease as determined by chest/abdominal/pelvic CT or physical exam
* Prior chemotherapy or radiation therapy for treatment of colorectal cancer
* Prior treatment with 5-FU
* Prior treatment with a tyrosine kinase inhibitor, EGFR inhibitor, or VEGF inhibitor
* Patients must not be receiving any other investigational agent
* Prior malignancy within the last 5 years except for completely excised skin cancer, in situ cervical cancer
* Warfarin anticoagulation
* Co-existent malignant disease
* Current or recent participation in a clinical trial (within 4 weeks from the first day of treatment)
* Pregnancy
* Blood pressure of \>150/100 mmHg
* Unstable angina
* NYHA Grade II or greater congestive heart failure
* History of myocardial infarction within 6 months
* History of stroke within 6 months
* Clinically significant peripheral vascular disease
* Evidence of bleeding diathesis or coagulopathy
* Presence of central nervous system or brain metastases
* Major surgical procedure, open biopsy, or significant trauma injury within 28 days prior to day 0, anticipation of need for major surgical procedure during the course of the study
* Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 0
* Pregnant or lactating
* Urine protein:creatinine ratio \> or equal to one at screening
* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to day 0\]
* Serious, non-healing wound, ulcer, or bone fracture

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No